Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 20, 2021
Reporting Period: Event date of August 20, 2021
The Company entered into a material definitive agreement to establish an "at-the-market" (ATM) equity distribution facility.
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, margins, debt, or liquidity metrics. The primary financial data point relates to the potential capital raise:
- Maximum Offering Size: Up to $30,000,000 in aggregate offering price.
- Compensation to Sales Agent: Up to 3.0% of the gross proceeds per share sold.
- Intended Use of Proceeds: Working capital and general corporate purposes.
Material Changes
The material change reported is the execution of an Equity Distribution Agreement with Oppenheimer & Co. Inc. on August 20, 2021. This agreement allows the Company to issue and sell shares of its common stock through the Sales Agent at prevailing market prices. The filing notes that the Company is not obligated to sell any shares, and no assurance is given regarding the price, amount, or timing of any future sales.
Guidance, Outlook, and Risks
Outlook: The Company expects to use net proceeds from the ATM Offering over time for working capital and general corporate purposes. The offering is subject to the Company's Registration Statement on Form S-3 (File No. 333-257558), declared effective on July 9, 2021.
Risks and Contingencies:
- Sale Uncertainty: The Company is under no obligation to make sales, and there is no assurance that any shares will be sold.
- Market Conditions: Sales will be made at prevailing market prices, which may fluctuate.
- Forward-Looking Statements: The report contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from expectations.
Investor Verification Checklist
- Verify the current market price of PCSA common stock to assess potential dilution impact.
- Review the full text of the Equity Distribution Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Confirm the status of the Form S-3 Registration Statement (File No. 333-257558) referenced in the filing.
- Monitor future filings for actual sales activity and proceeds generated under the ATM facility.